Regulatory updates and approvals

April has seen a number of important regulatory developments across the US, UK, Europe, and Japan, highlighting continued innovation in immunology, neurology, oncology, and metabolic disease.

In the United States, Sanofi received expanded FDA approval for Tzield (teplizumab) for children aged one year and older with stage 2 type 1 diabetes, allowing earlier intervention to delay progression to clinical disease. The approval was supported by phase 4 PETITE-T1D study data demonstrating safety and pharmacokinetic consistency in younger children.

The MHRA has approved a higher-dose regimen of Biogen’s Spinraza (nusinersen) for spinal muscular atrophy (SMA) in the UK. The updated dosing schedule introduces a faster loading phase and was supported by positive phase 2/3 DEVOTE study data, offering greater treatment flexibility for patients with 5q SMA.

Astellas Pharma also announced that the EMA has validated its application for PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as a perioperative treatment for muscle-invasive bladder cancer. Phase 3 data demonstrated significant reductions in tumour recurrence, progression, and death compared with standard chemotherapy.

In Japan, Sumitomo Pharma received conditional approval for Amchepry (raguneprocel), a stem cell-based dopamine neuron replacement therapy for Parkinson’s disease. Early clinical findings demonstrated improvements in motor function and evidence of dopamine-producing cell survival without tumour formation.

Meanwhile, Eli Lilly secured FDA approval for Foundayo (orforglipron), the first oral GLP-1 therapy for weight loss that can be taken without food or water restrictions. Clinical trial data showed meaningful weight reduction and improvements in cardiovascular risk markers.

Johnson & Johnson also received FDA approval for Icotyde (icotrokinra), a once-daily oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, supported by strong phase 3 ICONIC programme results.

Advances in research and innovative therapies

Research and clinical development continue to advance across respiratory disease, neurodegeneration, rare disease, and AI-enabled diagnostics.

AstraZeneca reported positive phase 3 MIRANDA trial results for tozorakimab in chronic obstructive pulmonary disease (COPD), showing significant reductions in moderate-to-severe exacerbations. The IL-33-targeting monoclonal antibody demonstrated benefits across multiple patient subgroups and disease severities.

AL-S Pharma released encouraging phase 2 data for AP-101 in amyotrophic lateral sclerosis (ALS). The investigational monoclonal antibody targeting misfolded SOD1 proteins demonstrated favourable safety results alongside biomarker reductions associated with neurodegeneration.

Grifols also announced proof-of-concept findings from its Chronos-PD programme, which combines AI, proteomics, and longitudinal real-world data to identify biological changes associated with Parkinson’s disease up to a decade before clinical diagnosis.

In rare disease research, Shionogi initiated a phase 2 clinical trial evaluating S-606001 for late-onset Pompe disease. The investigational therapy aims to reduce glycogen accumulation by inhibiting glycogen synthase activity, representing a novel substrate reduction approach.

AC Immune also expanded its collaboration with Eli Lilly to advance tau-targeting morphomer therapies for Alzheimer’s disease and other neurodegenerative disorders, with the agreement valued at more than $2 billion in potential milestone payments.

Roche opened a new Swiss Institute of Human Biology research facility in Basel, designed to support organoid research and AI-driven drug discovery initiatives as part of a wider €1.5 billion site investment.

Industry partnerships and global collaboration

Strategic collaborations and acquisitions remain central to strengthening pipelines, improving patient access, and accelerating therapeutic innovation.

myTomorrows partnered with Rare Disease Research to improve identification and referral pathways for patients entering rare disease clinical trials across the United States. The collaboration aims to streamline patient matching and improve referral efficiency.

Biogen expanded its immunology pipeline through an $850 million agreement with TJ Biopharma to obtain full global rights to felzartamab, an investigational CD38-targeting monoclonal antibody currently in phase 3 development for multiple immune-mediated diseases.

Eli Lilly also announced plans to acquire Kelonia Therapeutics in a deal valued at up to $7 billion, strengthening its capabilities in next-generation in vivo CAR-T therapies for oncology indications such as multiple myeloma.

START Center for Cancer Research partnered with Trialing to improve access to oncology clinical trials across Europe through enhanced physician engagement and real-time trial enrolment updates.

Additional acquisition activity included Novartis’ planned $2 billion acquisition of Excellergy to strengthen its allergy portfolio, Gilead Sciences’ $5 billion acquisition of ADC specialist Tubulis, Biogen’s $5.6 billion acquisition of Apellis Pharmaceuticals, and Eli Lilly’s proposed $7.8 billion acquisition of Centessa Pharmaceuticals to expand its neuroscience pipeline.

Healthcare policy and system developments

Healthcare systems and regulatory frameworks continue evolving to support innovation, ethical research practices, and patient-centred care.

The European Medicines Agency introduced three major enhancements to its PRIME scheme, including a regulatory roadmap, expedited scientific advice, and submission readiness meetings designed to accelerate development of treatments addressing unmet medical needs.

Pistoia Alliance launched patient research initiatives alongside publication of a best-practice framework for the ethical use of social media data in pharmaceutical research. The guidance addresses data privacy, AI use, study governance, and bias management within real-world evidence generation.

Allergan Aesthetics introduced the Skin Quality Index (SQI), a standardised framework aimed at improving communication between clinicians and patients during aesthetic medicine consultations through a unified clinical vocabulary.

Meanwhile, VML Health released its “Health Futures” report for World Health Day, highlighting key trends shaping healthcare communications, including preventive “early-signal” health monitoring, AI-driven personalisation, patient advocacy, and quality-of-life-focused care models.

Looking ahead

April’s developments demonstrate a rapidly evolving life sciences landscape shaped by regulatory innovation, AI-enabled research, strategic partnerships, and continued investment in rare disease, oncology, neuroscience, and metabolic health.

From first-in-class oral therapies and stem cell treatments to large-scale acquisitions and patient-centred healthcare initiatives, the sector continues to advance solutions for complex and underserved conditions.

Essjay Solutions will continue to monitor these developments and provide insights into the latest regulatory, clinical, research, and healthcare trends.